PRINCETON, N.J., Oct. 31 /CNW/ -- Novo Nordisk (NYSE: NVO), a global
healthcare company, today released its financial statement for the period
January 1, 2007 to September 30, 2007.
-- Novo Nordisk increased sales by 14% in local currencies and by 9% in
Danish kroner due to a significant negative currency development.
-- Sales of modern insulins increased by 37% (31% in Danish kroner).
-- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner).
-- Sales of Norditropin(R) increased by 12% (7% in Danish kroner).
-- Sales in North America increased by 25% (15% in Danish kroner).
-- Gross margin increased to 76.7% in the first nine months of 2007 up
from 75.2% in the same period last year, primarily reflecting continued
-- Operating profit increased by 11% to USD 1,410 million. Adjusted for
the impact from currencies, underlying operating profit increased by
more than 20%.
-- Net profit increased by 60% to USD 1,361 million, primarily reflecting
the divestment of Dako's business activities in the second quarter of
2007. Earnings per share (diluted) increased by 62% to USD 4.26.
-- The expectation for full-year sales growth is still 11-14% measured in
local currencies and now 6-9% as reported due to the depreciation of
key invoicing currencies. Full-year operating profit growth remains
unchanged around 20% measured in local currencies and is now expected
to be close to 10% as reported.
-- In October, Novo Nordisk received marketing authorization for
Levemir(R) in Japan for both type 1 and type 2 diabetes including
combination treatment with oral antidiabetics.
Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern
insulins continues to show strong sales growth in all key markets. Within the
next few months we will be launching Levemir(R) in FlexPen(R) in Japan, which
will further support growth in the coming years."
* For convenience, Danish kroner has been translated to USD in this
release, using the average exchange rate of USD 1.00 = DKK 5.54317.
Novo Nordisk is a healthcare company with an 84-year history of
innovation and achievement in diabetes care. The company has the broadest
diabetes product portfolio in the industry, including the most advanced
products within the area of insulin delivery systems.In addition to diabetes
care, Novo Nordisk has a leading position within areas such as hemostasis
management, growth hormone therapy, and hormone therapy for women. Novo
Nordisk's business is driven by the Triple Bottom Line: a commitment to
economic success, environmental soundness, and social responsibility to
employees and customers. With headquarters in Denmark, Novo Nordisk employs
more than 23,600 employees in 79 countries, and markets its products in 179
countries. Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock Exchange
under the symbol 'NVO'. For global information, visit novonordisk.com; for
United States information, visit novonordisk-us.com.
For further information:
For further information: Media, Sean Clements, +1-609-514-8316;
Investors, Christian Qvist Frandsen, +1-609-919-7937 Web Site: